About Us

Inflammatix focuses on the immune system’s interaction with disease.   Our team of experts in computational immunology, gene expression analysis, assay and algorithm development are building a diagnostic pipeline addressing unmet needs in sepsis, infectious disease, autoimmune disease, transplant rejection and other conditions.  We are initially focused on commercializing sepsis and infection diagnostics based on patent-pending biomarkers exclusively licensed from Stanford University.

Management

Timothy Sweeney, MD, PhD (Co-Founder and CEO)

Dr. Sweeney is a licensed physician and data scientist with >10 years of experience researching sepsis. After completing his MD/PhD at Duke University, he was a surgery resident at Stanford for 4 years. While training as a surgeon, he became frustrated with the current diagnostic tools for infection. During his residency research years, he completed a postdoc MS in Biomedical Informatics, during which he worked with Dr. Khatri to identify a new way to diagnose infections based on ‘reading’ the immune system. Their work designing custom informatics algorithms for sifting through heterogeneous large datasets led to the core technology on which Inflammatix is based.

Jonathan Romanowsky (Co-Founder and COO)

Jonathan has nearly 15 years of novel, high value molecular diagnostics commercialization experience.  He is driven by the incredible impact that diagnostics can provide dedicated healthcare professionals to improve patient care while providing significant value to public and private payers paying for it.  He has served in commercial leadership roles at Telomere Diagnostics, Veracyte, CardioDx and CareDx.  He has successfully brought product concepts through launch and to achieve standard-of-care status.  He has lead numerous commercialization efforts in product management, marketing, operations, reimbursement and sales in the United States and abroad.  Prior to a career in molecular diagnostics, Jonathan pioneered electronic prescribing at iScribe (now part of CVS). Jonathan began his career as a strategic consultant for Bain & Company.  Jonathan earned his Bachelor of Science in Political Economy from the University of California, Berkeley and his MBA from Stanford University, focusing on medical technology innovation.

Purvesh Khatri, PhD (Co-Founder and Scientific Advisor)

Dr. Khatri is an Assistant Professor at the Stanford Institute for Immunity, Transplantation, and Infection and the Center for Biomedical Informatics Research, Department of Medicine. Dr. Khatri has more than 15 years of professional experience in the areas of bioinformatics, computational biology, and translational medicine. He is well known for work on the development of ontological and pathway analysis of high throughput molecular data, and for the integration and analysis of high throughput genomics and proteomics data. Dr. Khatri developed the first tool, Onto-Express, for analysis of microarray data using Gene Ontology. He expanded his work in ontological analysis to develop a suite of web-based open access tools, Onto-Tools. His recent work is focused on developing computational methods for integrated, multi-cohort analysis of publically available data to increase the sample size as well as better account for heterogeneity observed in real world patient population. Using these methods, he has identified highly specific and sensitive biomarkers for:  (1) acute solid-organ transplant rejection, (2) cancers (pancreatic cancer, small cell and non-small cell lung cancer, mesothelioma), and (3) infectious diseases (sepsis, respiratory viral infections, tuberculosis).

Investors

Inflammatix series A financing was lead by Khosla Ventures. Also participating in round was the Stanford-Startx Fund, which was co-founded by the StartX accelerator, Stanford University and Stanford Health Care.